HPV-Positive Oropharyngeal Cancer: An Umbrella Review of Global Prevalence and Survival Outcomes

Mohammed Khalid Mahmood; Balen Hamid Qadir; Balkees Taha Garib; Yad Mariwan Mohammed Ali; Ariwan  Othman Saeed; Herve  Tassery; Delphine Tardivo; Romain Lan

doi:10.24017/

Authors

Mohammed Khalid Mahmood Faculty of Medical and Paramedical Sciences, Aix-Marseille University, French National Center of Scientific Research (CNRS), French Blood Establishment (EFS), Bio-Cultural Anthropology, Law, Ethics and Health Laboratory (ADES), 13005 Marseille, France. https://orcid.org/0000-0002-8093-9514
Balen Hamid Qadir Department of Dentistry, Komar University of Science and technology, Sulaymaniyah, Iraq.
Balkees Taha Garib Dentistry College, University of Sulaimani, Sulaymaniyah, Iraq
Yad Mariwan Mohammed Ali Department of Dentistry, Tishk International University, Sulaymaniyah, Iraq.
Ariwan Othman Saeed Zhianawa Cancer Center, Sulaymaniyah, Iraq| College of Medicine, Sulaymaniyah University, Sulaymaniyah, Iraq.
Herve Tassery Faculty of Medical and Paramedical Sciences, Aix-Marseille University, French National Center of Scientific Research (CNRS), French Blood Establishment (EFS), Bio-Cultural Anthropology, Law, Ethics and Health Laboratory (ADES), 13005 Marseille, France. https://orcid.org/0000-0002-1471-5651
Delphine Tardivo Faculty of Medical and Paramedical Sciences, Aix-Marseille University, French National Center of Scientific Research (CNRS), French Blood Establishment (EFS), Bio-Cultural Anthropology, Law, Ethics and Health Laboratory (ADES), 13005 Marseille, France. https://orcid.org/0000-0003-2952-4425
Romain Lan Faculty of Medical and Paramedical Sciences, Aix-Marseille University, French National Center of Scientific Research (CNRS), French Blood Establishment (EFS), Bio-Cultural Anthropology, Law, Ethics and Health Laboratory (ADES), 13005 Marseille, France.

Abstract

Human papillomavirus (HPV) has transformed oropharyngeal cancer (OPC) epidemiology, creating distinct disease entities. This umbrella reviews synthesized evidence on HPV-positive OPC prevalence and survival. Four databases were searched for systematic reviews (SRs) examining HPV prevalence and survival in OPC. Meta-analysis was performed using random effects methodology. Quality was assessed using A Measurement Tool to Assess systematic Reviews 2 (AMSTAR 2) and evidence certainty was rated by utilizing Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool. A Corrected Covered Area (CCA) analysis was conducted to measure the degree of overlapping literature among the included SRs. Twenty-four SRs encompassing 783 primary studies and 146,218 OPC patients were included. Overall HPV prevalence was 43% (95% CI: 41-46%). HPV-16 predominated (79%), with highest prevalence in tonsils (60%), followed by base of tongue (43%). The pooled prevalence of HPV in soft palate was 8%. Males showed higher prevalence than females (47% vs. 35%). North America had the highest regional prevalence (59%), followed by Oceanica (49%), Europe (44%), and Asia (37%). The comparison of the meta-analyses (MAs) before and after 2020 showed a reduction in prevalence from 48% to 41%, although the difference was not statistically significant. For the virus detection method, p16 and in situ hybridization positivity resulted in higher prevalences compared to Polymerase Chain Reaction (PCR) alone. Significant presence of heterogeneity and publication bias, large CIs and the observational nature of the included study designs led to "low" evaluation of all the pooled analyses assessed by GRADE. HPV-positive patients demonstrated superior survival outcomes, though HPV-non16 subtypes showed poorer prognosis. In conclusion, HPV affects nearly half of OPC cases globally, with significant anatomical, demographic, and geographic variations. These findings support individualized treatment approaches beyond binary HPV status classification.

Keywords:

Human papillomavirus, oropharyngeal cancer, prevalence, survival, systematic review

References

A. F. Carlander et al., “A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide,” Viruses, vol. 13, no. 7, p. 1326, 2021, doi: https://doi.org/10.3390/v13071326.

M. Zamani et al., “The current epidemic of HPV-associated oropharyngeal cancer: an 18-year Danish population-based study with 2,169 patients,” European Journal of Cancer, vol. 134, pp. 52–59, 2020, doi: https://doi.org/10.1038/s41388-023-02819-y.

T. Guo, S. Y. Kang, and E. E. Cohen, “Current perspectives on recurrent HPV-mediated oropharyngeal cancer,” Frontiers in Oncology, vol. 12, p. 966899, 2022, doi: https://doi.org/10.3389/fonc.2022.966899.

M. Lechner, J. Liu, L. Masterson, and T. R. Fenton, “HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management,” Nattional Reviews in Clinical Oncology, vol. 19, no. 5, pp. 306–327, 2022, doi: 10.1038/s41571-022-00603-7.

C. T. Allen, J. S. Lewis, S. K. El‐Mofty, B. H. Haughey, and B. Nussenbaum, “Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications,” The Laryngoscope, vol. 120, no. 9, pp. 1756–1772, Sep. 2010, doi: 10.1002/lary.20936.

D. R. Lowy and K. Munger, “Prognostic implications of HPV in oropharyngeal cancer,” New England Journal of Medicine, vol. 363, no. 1, pp. 82–4, 2010, https://hpvinfo.com.br/artigos/HPV-Orofaringe2.pdf.

K. K. Ang et al., “Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer,” New England Journal of Medicine, vol. 363, no. 1, pp. 24–35, Jul. 2010, doi: 10.1056/NEJMoa0912217.

H. Mirghani et al., “Treatment de‐escalation in HPV‐positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives,” International Journal of Cancer, vol. 136, no. 7, pp. 1494–1503, Apr. 2015, doi: 10.1002/ijc.28847.

J. J. Kang et al., “Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer,” CA. A Cancer Journal for Clinicians, vol. 73, no. 2, pp. 164–197, Mar. 2023, doi: 10.3322/caac.21758.

W. Borena et al., “HPV-induced oropharyngeal cancer and the role of the E7 oncoprotein detection via brush test,” Cancers, vol. 12, no. 9, p. 2388, 2020, doi: https://doi.org/10.3390/cancers12092388.

L. Oton-Gonzalez et al., “Serum HPV16 E7 oncoprotein is a recurrence marker of oropharyngeal squamous cell carcinomas,” Cancers, vol. 13, no. 13, p. 3370, 2021, doi: https://doi.org/10.3390/cancers13133370.

C. C. Fossum, A. V. Chintakuntlawar, D. L. Price, and J. J. Garcia, “Characterization of the oropharynx: anatomy, histology, immunology, squamous cell carcinoma and surgical resection,” Histopathology, vol. 70, no. 7, pp. 1021–1029, 2017, doi: https://doi.org/10.1111/his.13140.

L. B. Campos et al., “Oncoviruses in the oral cavity: recent advances in understanding viral infections and tumorigenesis,” Internationl Journal of Molecular Science, vol. 26, no. 14, p. 6721, 2025, doi: https://doi.org/10.3390/ijms26146721.

H. Miniggio, “Biological significance of palatine tonsillar epithelium: microstructure and disease,” South African Dental Journal, vol. 71, no. 10, pp. 496–499, 2016, https://hdl.handle.net/10520/EJC-7c1a621c0.

J. D. Howard and C. H. Chung, “Biology of human papillomavirus–related oropharyngeal cancer,” in Seminars in Radiation Oncology, Elsevier, 2012, pp. 187–193. Accessed: Jun. 14, 2026. [Online]. Available: https://www.sciencedirect.com/science/article/pii/S1053429612000215

A. M. Evans, M. Salnikov, S. F. Gameiro, S. Maleki Vareki, and J. S. Mymryk, “HPV-positive and-negative cervical cancers are immunologically distinct,” Journal of Clinical Medicine, vol. 11, no. 16, p. 4825, 2022, doi: https://doi.org/10.3390/jcm11164825.

M. B. Wang, I. Y. Liu, J. A. Gornbein, and C. T. Nguyen, “HPV‐Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis,” Otolaryngology and Neck Surgery, vol. 153, no. 5, pp. 758–769, Nov. 2015, doi: 10.1177/0194599815592157.

M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” bmj, vol. 372, 2021, Accessed: Jun. 14, 2026, doi: doi: 10.1136/bmj.n71.

B. J. Shea et al., “AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both,” bmj, vol. 358, 2017, Accessed: Jun. 14, 2026, doi: doi: 10.1136/bmj.j4008.

R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986, doi: 10.1016/0197-2456(86)90046-2.

H. Jpt, “Cochrane handbook for systematic reviews of interventions,” Httpwww Cochrane-Handb. Org, 2008, Accessed: Jun. 14, 2026. [Online]. Available: https://cir.nii.ac.jp/crid/1571980075694747776

M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” bmj, vol. 315, no. 7109, pp. 629–634, 1997, doi: doi: 10.1136/bmj.315.7109.629.

J. T. Fekete and B. GyHorffy, “MetaAnalysisOnline. com: web-based tool for the rapid meta-analysis of clinical and epidemiological studies,” Journal of Medical Internet Research, vol. 27, p. e64016, 2025, doi: https://doi.org/10.2196/64016.

G. H. Guyatt et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” Bmj, vol. 336, no. 7650, pp. 924–926, 2008, https://cir.nii.ac.jp/crid/1370853567793495940.

D. Pieper, S.-L. Antoine, T. Mathes, E. A. Neugebauer, and M. Eikermann, “Systematic review finds overlapping reviews were not mentioned in every other overview,” Journal of Clinical Epidemiology, vol. 67, no. 4, pp. 368–375, 2014, https://doi.org/10.1016/j.jclinepi.2013.11.007.

C. G. L. Hobbs, J. A. C. Sterne, M. Bailey, R. S. Heyderman, M. A. Birchall, and S. J. Thomas, “Human papillomavirus and head and neck cancer: a systematic review and meta-analysis.,” Clinical Otolaryngology, vol. 31, no. 4, 2006, Accessed: Jun. 14, 2026. [Online]. Available: http://www.drchrishobbs.com/uploads/8/2/1/2/8212308/hpv__hnscc.pdf

F. Dayyani, C. J. Etzel, M. Liu, C.-H. Ho, S. M. Lippman, and A. S. Tsao, “Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC),” Head and Neck Oncology, vol. 2, no. 1, p. 15, Dec. 2010, doi: 10.1186/1758-3284-2-15.

S. Abogunrin, G. L. Di Tanna, S. Keeping, S. Carroll, and I. Iheanacho, “Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis,” BMC Cancer, vol. 14, no. 1, p. 968, Dec. 2014, doi: 10.1186/1471-2407-14-968.

A. M. Al Fadel, K. K. Jakobsen, L. H. Jensen, A.-L. F. Carlander, C. Grønhøj, and C. von Buchwald, “The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue- a systematic review and meta-analysis,” Oral Oncology, vol. 165, p. 107311, 2025, doi: 10.1016/j.oraloncology.2025.107311.

M. Cui et al., “Characteristics of human papillomavirus infection among oropharyngeal cancer patients: A systematic review and meta-analysis,” Archives of Oral Biology, vol. 157, p. 105830, 2024, doi: 10.1016/j.archoralbio.2023.105830.

T. C. Fonsêca et al., “Global prevalence of human papillomavirus-related oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis,” Clinical Oral Investigations, vol. 28, no. 1, p. 62, Dec. 2023, doi: 10.1007/s00784-023-05425-0.

C. Gotz, C. Bischof, K.-D. Wolff, and A. Kolk, “Detection of HPV infection in head and neck cancers: Promise and pitfalls in the last ten years: A meta-analysis,” Molecualr and Clinical Oncology, Oct. 2018, doi: 10.3892/mco.2018.1749.

L. Guo et al., “Prevalence of human papillomavirus type-16 in head and neck cancer among the Chinese population: a meta-analysis,” Frontiers in Oncology, vol. 8, p. 619, 2018, doi: 10.3389/fonc.2018.00619.

L. Haeggblom, T. Ramqvist, M. Tommasino, T. Dalianis, and A. Näsman, “Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years,” Papillomavirus Research, vol. 4, pp. 1–11, 2017, doi: https://doi.org/10.1016/j.pvr.2017.05.002.

X. Ju et al., “High‐Risk Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma Among Non‐Indigenous and Indigenous Populations: A Systematic Review,” Otolaryngology and Neck Surgery, vol. 165, no. 1, pp. 23–32, Jul. 2021, doi: 10.1177/0194599820975042.

Y. Lu et al., “Human papillomavirus and P16INK4A in oropharyngeal squamous cell carcinomas: A systematic review and meta‐analysis,” Internation Journal of Cancer, vol. 154, no. 5, pp. 830–841, Mar. 2024, doi: 10.1002/ijc.34763.

B. A. L. A. Mariz et al., “Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: A systematic review and meta-analysis,” Critical Reviews in Oncology and Hematology, vol. 156, p. 103116, 2020, doi: 10.1016/j.critrevonc.2020.103116.

H. Mehanna et al., “Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta‐analysis of trends by time and region,” Head & Neck, vol. 35, no. 5, pp. 747–755, May 2013, doi: 10.1002/hed.22015.

C. Ndiaye et al., “HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis,” Lancet Oncology, vol. 15, no. 12, pp. 1319–1331, 2014, doi: 10.1016/S1470-2045(14)70471-1.

A. C. Oliveira, I. C. Cavalcanti De Lima, V. M. Frez Marques, W. H. Alves De Araújo, and C. De Campos Ferreira, “Human papillomavirus prevalence in oral and oropharyngeal squamous cell carcinoma in South America: A systematic review and meta-analysis,” Oncology Review, vol. 16, no. 1, Mar. 2022, doi: 10.4081/oncol.2022.552.

C. Ragin et al., “Prevalence of HPV infection in racial–ethnic subgroups of head and neck cancer patients,” Carcinogenesis, vol. 38, no. 2, pp. 218–229, 2017, doi: 10.1093/carcin/bgw203.

S. Sasidharanpillai, N. Ravishankar, V. Kamath, P. V. Bhat, P. Bhatt, and G. Arunkumar, “Prevalence of human papillomavirus (HPV) DNA among men with oropharyngeal and anogenital cancers: a systematic review and meta-analysis,” Asian Pacific Journal of Cancer Prevention, vol. 22, no. 5, p. 1351, 2021, doi: 10.31557/APJCP.2021.22.5.1351.

M. H. Shaikh, N. A. McMillan, and N. W. Johnson, “HPV-associated head and neck cancers in the Asia Pacific: A critical literature review & meta-analysis,” Cancer Epidemiology, vol. 39, no. 6, pp. 923–938, 2015, doi: 10.1016/j.canep.2015.09.013.

A. P. Stein, S. Saha, M. Yu, R. J. Kimple, and P. F. Lambert, “Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time,” Chemical Research in Toxicology, vol. 27, no. 4, pp. 462–469, Apr. 2014, doi: 10.1021/tx500034c.

N. V. Vani, R. Rama, R. Madhanagopal, R. Vijayalakshmi, and R. Swaminathan, “Human Papillomavirus–Attributable Head and Neck Cancers in India—A Systematic Review and Meta-Analysis,” JCO Global Oncology, no. 10, p. e2300464, Mar. 2024, doi: 10.1200/GO.23.00464.

E. Stein, N. R. Lenze, W. G. Yarbrough, D. N. Hayes, A. Mazul, and S. Sheth, “Systematic review and meta‐analysis of racial survival disparities among oropharyngeal cancer cases by HPV status,” Head & Neck, vol. 42, no. 10, pp. 2985–3001, Oct. 2020, doi: 10.1002/hed.26328.

S. Y. Chen et al., “The association of smoking and outcomes in HPV-positive oropharyngeal cancer: A systematic review,” American Journal of Otolaryngology, vol. 41, no. 5, p. 102592, 2020, doi: 10.1016/j.amjoto.2020.102592.

N. R. Lenze, D. R. Farquhar, A. L. Mazul, M. M. Masood, and J. P. Zevallos, “Racial disparities and human papillomavirus status in oropharyngeal cancer: A systematic review and meta‐analysis,” Head & Neck, vol. 41, no. 1, pp. 256–261, Jan. 2019, doi: 10.1002/hed.25414.

A. R. Marrero-Gonzalez, E. S. Chernov, S. A. Nguyen, B. A. Keith, M. N. Stevens, and A. E. Kejner, “Sex and human papillomavirus in oropharyngeal cancer: A systematic review and meta-analysis,” American Journal of Otolaryngology, vol. 45, no. 6, p. 104464, 2024, doi: 10.1016/j.amjoto.2024.104464.

M. A. O’Rorke, M. V. Ellison, L. J. Murray, M. Moran, J. James, and L. A. Anderson, “Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis,” Oral Oncology, vol. 48, no. 12, pp. 1191–1201, 2012, doi: 10.1016/j.oraloncology.2012.06.019.

R. F. Shenker, N. B. Razavian, R. B. D’Agostino Jr, Y. M. Mowery, D. M. Brizel, and R. T. Hughes, “Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis,” Oral Oncology, vol. 148, p. 106644, 2024, doi: 10.1016/j.oraloncology.2023.106644.

K. Kobayashi, K. Hisamatsu, N. Suzui, A. Hara, H. Tomita, and T. Miyazaki, “A review of HPV-related head and neck cancer,” Journal of Clinical Medicine, vol. 7, no. 9, p. 241, 2018, doi: 10.3390/jcm7090241.

A. Hammer, A. Rositch, F. Qeadan, P. E. Gravitt, and J. Blaakaer, “Age‐specific prevalence of HPV 16/18 genotypes in cervical cancer: A systematic review and meta‐analysis,” International Journal of Cancer, vol. 138, no. 12, pp. 2795–2803, Jun. 2016, doi: 10.1002/ijc.29959.

A.-B. Moscicki et al., “Updating the natural history of human papillomavirus and anogenital cancers,” Vaccine, vol. 30, pp. F24–F33, 2012, https://doi.org/10.1016/j.vaccine.2012.05.089.

T. B. Olesen et al., “Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis,” Lancet Oncology, vol. 20, no. 1, pp. 145–158, 2019, doi: 10.1016/S1470-2045(18)30682-X.

A. K. Mattox et al., “Myeloid cells are enriched in tonsillar crypts, providing insight into the viral tropism of human papillomavirus,” American Journal of Pathology, vol. 191, no. 10, pp. 1774–1786, 2021, doi: 10.1016/j.ajpath.2021.06.012.

Y. X. Lim, M. L. Mierzwa, M. A. Sartor, and N. J. D’Silva, “Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer,” Oncogene, vol. 42, no. 40, pp. 2939–2955, 2023, doi: 10.1038/s41388-023-02819-y.

S. Roberts, D. Evans, H. Mehanna, and J. L. Parish, “Modelling human papillomavirus biology in oropharyngeal keratinocytes,” Philosophical Transactions of the Royal Society B Biology and Science, vol. 374, no. 1773, 2019, doi: 10.1098/rstb.2018.0289.

M. A. Villarroel, A. M. Galinksy, P.-J. Lu, and C. Pingali, “Human papillomavirus vaccination coverage in children ages 9–17 years: United States, 2022,” 2024, Accessed: Jun. 14, 2026. [Online]. Available: https://stacks.cdc.gov/view/cdc/145593

A. Tsentemeidou et al., “Human papillomavirus vaccine to end oropharyngeal cancer. A systematic review and meta-analysis,” Sexually Transmmitted Diseases, vol. 48, no. 9, pp. 700–707, 2021, doi: 10.1097/OLQ.0000000000001405.

J. Zhang, Z. Qin, C. Lou, J. Huang, and Y. Xiong, “The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis,” Public Health, vol. 196, pp. 165–171, 2021, doi: https://doi.org/10.1016/j.puhe.2021.05.012.

P. Garutti, S. Montori, E. Bazzan, and C. Tarabbia, “Gender differences in the epidemiology and prevention of human papillomavirus (HPV) and HPV-related diseases,” Journal of Sex- and Gender-Specific Medicine, vol. 4, no. 4, p. 152, 2018, doi: 10.1723/3091.30836.

R. M. Lewis, L. E. Markowitz, J. W. Gargano, M. Steinau, and E. R. Unger, “Prevalence of genital human papillomavirus among sexually experienced males and females aged 14–59 years, United States, 2013–2014,” Journal of Infectious Diseases, vol. 217, no. 6, pp. 869–877, 2018, doi: 10.1093/infdis/jix655.

C. Ragin et al., “Oral HPV infection and sexuality: a cross-sectional study in women,” International Journal of Molecular Science, vol. 12, no. 6, pp. 3928–3940, 2011, doi: 10.3390/ijms12063928.

G. D’Souza, K. Cullen, J. Bowie, R. Thorpe, and C. Fakhry, “Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection,” PloS One, vol. 9, no. 1, p. e86023, 2014, doi: 10.1371/journal.pone.0086023.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, Nov. 2018, doi: 10.3322/caac.21492.

S. Marur, G. D’Souza, W. H. Westra, and A. A. Forastiere, “HPV-associated head and neck cancer: a virus-related cancer epidemic,” Lancet Oncology, vol. 11, no. 8, pp. 781–789, 2010, https://doi.org/10.1016/S1470-2045(10)70017-6.

G. D’Souza et al., “Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer,” New England Journal of Medicine, vol. 356, no. 19, pp. 1944–1956, May 2007, doi: 10.1056/NEJMoa065497.

M. L. Gillison et al., “Prevalence of oral HPV infection in the United States, 2009-2010,” Jama, vol. 307, no. 7, pp. 693–703, 2012, doi:10.1001/jama.2012.101.

P. M. Weinberger et al., “Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis,” Journal of Clinical Oncology, vol. 24, no. 5, pp. 736–747, Feb. 2006, doi: 10.1200/JCO.2004.00.3335.

J. S. Lewis Jr et al., “Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists,” Archives of Pathology & Laboratory Medicine, vol. 142, no. 5, pp. 559–597, 2018, doi: https://doi.org/10.5858/arpa.2017-0286-CP.

H. Mirghani, F. Amen, F. Moreau, and J. L. St Guily, “Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?,” Oral Oncology, vol. 51, no. 3, pp. 229–236, 2015, doi: https://doi.org/10.1016/j.oraloncology.2014.11.011.

C. Fakhry et al., “Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline,” Journal of Clinical Oncology, vol. 36, no. 31, pp. 3152–3161, Nov. 2018, doi: 10.1200/JCO.18.00684.

B. A. Werness, A. J. Levine, and P. M. Howley, “Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53,” Science, vol. 248, no. 4951, pp. 76–79, Apr. 1990, doi: 10.1126/science.2157286.

H. C. Hafkamp et al., “A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8,” International Journal of Cancer, vol. 107, no. 3, pp. 394–400, Nov. 2003, doi: 10.1002/ijc.11389.

D. E. Symer et al., “Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers,” Genome Research, vol. 32, no. 1, p. 55, 2022, doi: https://doi.org/10.1101/gr.275911.121.

N. Stransky et al., “The Mutational Landscape of Head and Neck Squamous Cell Carcinoma,” Science, vol. 333, no. 6046, pp. 1157–1160, Aug. 2011, doi: 10.1126/science.1208130.

F. P. Worden et al., “Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3138–3146, Jul. 2008, doi: 10.1200/JCO.2007.12.7597.

S. Lyford-Pike et al., “Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma,” Cancer Research, vol. 73, no. 6, pp. 1733–1741, 2013, doi: https://doi.org/10.1158/0008-5472.CAN-12-2384.